CSL Limited Annual Report 2022/23 61 Board of Directors Brian McNamee AO MBBS, FTSE Age 66 Chair and Independent Non-Executive Director Director of CSL Limited since February 2018 and Chair fromOctober 2018. Dr McNamee has deep executive experience in the biopharmaceutical industry, with a focus on strategy and creating long-term shareholder value. Dr McNamee was the Chief Executive Officer and Managing Director of CSL from 1990 until 2013. Since leaving his executive role at CSL, Dr McNamee has served as a senior advisor to private equity group Kohlberg Kravis Roberts. He has also pursued a number of private equity and interests in small cap healthcare companies, and in 2014 served on the panel of the Australian Government’s Financial System Inquiry. In 2009, he was made an Officer of the Order of Australia for service to business and commerce. Other directorships and offices (current and recent): – Chair of Geoff Ogilvy Foundation (since May 2021); and – Former Chair of GenesisCare Limited (from July 2019 to June 2022). Board Committee memberships: – Member of the Innovation and Development Committee; and – Member of the Corporate Governance and Nomination Committee. Paul McKenzie PhD (Chemical Engineering) Age 57 Non-Independent Executive Director Director of CSL Limited since December 2022, and appointed Chief Executive Officer and Managing Director in March 2023. Dr McKenzie was appointed Chief Executive Officer and Managing Director of CSL Limited on 6 March 2023. Paul has more than 30 years of leadership experience in the global biotechnology industry, including managing complex organisations through compelling growth and transformation. After joining CSL as Chief Operating Officer in June 2019, Dr McKenzie was accountable for optimising CSL’s operations and business growth. He transformed CSL’s global end-to-end operations, advanced CSL Seqirus’ differentiated portfolio strategy, and led CSL Plasma through COVID-19 challenges while surpassing plasma collection volumes beyond pre-pandemic levels. Prior to joining CSL, Dr McKenzie was executive vice president of Pharmaceutical Operations & Technology at Biogen. He also served in a range of progressively senior level roles in R&D and manufacturing at Johnson & Johnson, Bristol-Myers Squibb and Merck. Dr McKenzie was elected to the US National Academy of Engineering in 2020. He holds a Bachelor of Science degree in chemical engineering from the University of Pennsylvania and a PhD in chemical engineering from Carnegie Mellon University. Board Committee memberships: – Member of the Innovation and Development Committee. Bruce Brook BCom, BAcc, FCA, MAICD Age 68 Independent Non-Executive Director Director of CSL Limited since August 2011. Mr Brook has an extensive breadth of executive experience in diverse industries, including mining, finance, manufacturing and chemicals. In particular, Mr Brook has valuable insight and experience in relation to risk, capital discipline, change management, corporate culture and creating shareholder value. Mr Brook was chief financial officer of WMC Resources Limited from 2002 to 2005. He also held key executive roles including deputy chief finance officer of ANZ Banking Group Limited, group chief accountant of Pacific Dunlop Limited and general manager, Group Accounting positions at CRA Limited and Pasminco Limited. Other directorships and offices (current and recent): – Director of Djerriwarrh Investments Limited (since August 2021); – Director of Guide Dogs Victoria (since November 2018); – Director of Incitec Pivot Limited (since December 2018); and – Director of Newmont Corporation (since October 2011). Board Committee Memberships: – Chair of the Audit and Risk Management Committee; and – Member of the Corporate Governance and Nomination Committee.
RkJQdWJsaXNoZXIy MjE2NDg3